Evotec SE and Takeda Pharmaceutical Company Ltd have entered a strategic drug discovery collaboration potentially worth $850m.
Under the agreement, Evotec will develop at least five small molecule discovery programmes against targets identified by Takeda in oncology, gastroenterology, neuroscience and rare diseases. Takeda will have the option to assume responsibility at lead series and upon Evotec delivering a pre-clinical candidate.
Under the terms of the collaboration, Takeda will pay Evotec an undiclosed upfront fee to get access to its platforms. Additionally, Evotec is eligible to receive pre-clinical, clinical, and commercial milestones that can total in excess of $170 m per programme as well as tiered royalties on future sales.
AMR: GARDP and Entasis Therapeutics start pivotal study
Latest NewsJane Osbourn joins Mogrify Board
AppointmentsBritish cell therapy expert Mogrify Ltd has appointed Jane Osbourn as Chair of the Board. Osbourn will also become a Member of the Scientific Advisory Board and support Mogrifiy’s executive team in therapeutic programme selection, industrial partner development, mentoring and investor relations.
BASF broadens biotech business by Isobionics acquisition
Latest NewsBASF SE has strengthened its capabilities in recombinant production of natural ingredients by acquiring Dutch Isobionics BV and collaborating with Conagen Inc.
2nd ECP Summer Summit at Henkel HQ, Düsseldorf
Latest News290 participants from 18 nations at the late summer edition of the European Chemistry Partnering in Düsseldorf
Gut bacterial enzyme keeps inflammation away
Latest NewsAn antimicrobial molecule produced by the human microbiota gut may help fight drug-resistant infections.
Tacalyx GmbH raises €7m in seed funding
Latest NewsEvotec and Takeda enter drug discovery deal
Latest NewsEvotec SE and Takeda Pharmaceutical Company Ltd have entered a strategic drug discovery collaboration potentially worth $850m.
Under the agreement, Evotec will develop at least five small molecule discovery programmes against targets identified by Takeda in oncology, gastroenterology, neuroscience and rare diseases. Takeda will have the option to assume responsibility at lead series and upon Evotec delivering a pre-clinical candidate.
Under the terms of the collaboration, Takeda will pay Evotec an undiclosed upfront fee to get access to its platforms. Additionally, Evotec is eligible to receive pre-clinical, clinical, and commercial milestones that can total in excess of $170 m per programme as well as tiered royalties on future sales.
BioBLU® 10c Single-Use Vessel
ProductsThe important link for bioprocess scale-up!
EMA greenlights new medicines
Latest NewsAt its September meeting, the EMA’s CHMP recommended three innovative medicines for EU market approval.
New malaria lead kills 99.9% of pathogens
Latest NewsDutch and US researchers have re-engineered non-druggable compounds that block the transmission and metabolism of the malaria parasite Plasmodium falciparum.